Simulations suggest pharmacological methods for rescuing long-term potentiation

Journal of Theoretical Biology

Volumn 360, Issue , 2014, Pages 243-250

  Smolen, Paul ^a   Baxter, Douglas A ^a   Byrne, John H ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cognitive disorders; Combination therapy; Drug synergism; Long term memory; Rubinstein Taybi syndrome

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHODIESTERASE INHIBITOR; BONE SIALOPROTEIN (35-62), HUMAN; PEPTIDE FRAGMENT; SIALOGLYCOPROTEIN;

COGNITION; DRUG; INHIBITOR; MOLECULAR ANALYSIS; PROTEIN; SIMULATION; SYNERGISM;

ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HISTONE ACETYLATION; LONG TERM POTENTIATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RUBINSTEIN SYNDROME; SIMULATION; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MUTATION; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RUBINSTEIN-TAYBI SYNDROME;

COMPUTER SIMULATION; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; LONG-TERM POTENTIATION; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MUTATION; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; RUBINSTEIN-TAYBI SYNDROME; SIALOGLYCOPROTEINS;

EID: 84905399815     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2014.07.006     Document Type: Article

References (57)

1. Abraham W.C., Logan B., Greenwood J.M., Dragunow M. Induction and experience-dependent consolidation of stable long-term potentiation lasting months in the hippocampus. J. Neurosci. 2002, 22:9626-9634.
2. +/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004, 42:947-959.
3. Barco A. The Rubinstein-Taybi syndrome: modeling mental impairments in the mouse. Genes Brain Behav. 2007, 6(Suppl. 1):S32-S39.
4. Barco A., Alarcon J.M., Kandel E.R. Expression of constitutively active CREB facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 2002, 108:689-703.
5. Barrera N.P., Morales B., Torres S., Villalon M. Principles: mechanisms and modeling of synergism in cellular responses. Trends Pharmacol. Sci. 2005, 26:526-532.
6. Barrett R.M., Malvaez M., Kramar E., Matheos D.P., Arrizon A., Cabrera S.M., Lynch G., Greene W., Wood M.A. Hippocampal focal knockout of CBP affects specific histone modifications, long-term potentiation, and long-term memory. Neuropsychopharmacology 2011, 36:1545-1556.
7. Bhalla U.S., Iyengar R. Emergent properties of networks of biological signaling pathways. Science 1999, 283:381-387.
8. Bijnsdorp I.V., Giovannetti E., Peters G.J. Analysis of drug interactions. Methods Mol. Biol. 2011, 731:421-434.
9. Boran A.D., Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Dev. 2010, 13:297-309.
10. Bourtchouladze R., Lidge R., Catapano R., Stanley J., Gossweiler S., Romashko D., Tully T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of PDE 4. Proc. Natl. Acad. Sci. USA 2003, 100:10518-10522.
11. Burden R.L., Faires J.D. Numerical Analysis 2005, Brooks-Cole Pub. Co, Pacific Grove, California.
12. Chen H.X., Otmakhov N., Strack S., Colbran R.J., Lisman J.E. Is persistent activity of calcium/calmodulin-dependent kinase required for the maintenance of LTP?. J. Neurophysiol. 2001, 85:1368-1376.
13. Corti S., Nizzardo M., Simone C., Falcone M., Nardini M., Ronchi D., Donadini C., Salani S., Riboldi G., Magri F., Menozzi G., Bonaglia C., Rizzo F., Bresolin N., Comi G.P. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 2012, 4:165ra162.
14. Ehninger D., Silva A.J. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol. Med. 2011, 17:78-87.
15. English J.D., Sweatt J.D. A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J. Biol. Chem. 1997, 272:19103-19106.
16. Foulds C.E., Nelson M.L., Blaszczak A.G., Graves B.J. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol. Cell. Biol. 2004, 24:10954-10964.
17. Frey U., Morris R.G. Synaptic tagging and long-term potentiation. Nature 1997, 385:533-536.
18. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br. J. Pharmacol. 2008, 155:288-290.
19. Graff J., Mansuy I.M. Epigenetic dysregulation in cognitive disorders. Eur. J. Neurosci. 2009, 30:1-8.
20. Guilding C., McNair K., Stone T.W., Morris B.J. Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB. Eur. J. Neurosci. 2007, 25:99-105.
21. Hayer A., Bhalla U.S. Molecular switches at the synapse emerge from receptor and kinase traffic. PLoS Comput. Biol. 2005, 1:137-154.
22. Hevroni D., Rattner A., Bundman M., Lederfein D., Gabarah A., Mangelus M., Silverman M.A., Kedar H., Naor C., Kornuc M., Hanoch T., Seger R., Theill L.E., Nedivi E., Richter-Levin G., Citri Y. Hippocampal plasticity involves extensive gene induction and multiple cellular mechanisms. J. Mol. Neurosci. 1998, 10:75-98.
23. 2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron 1998, 21:869-883.
24. Kazantsev A.G., Thompson L.M. Therapeutic application of deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
25. Kida G. A functional role for CREB as a positive regulator of memory formation and LTP. Exp. Neurobiol. 2012, 21:136-140.
26. Korzus E., Rosenfeld M.G., Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004, 42:961-972.
27. Levenson J.M., O'Riordan K.J., Brown K.D., Trinh M.A., Molfese D.L., Sweatt J.D. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 2004, 279:40545-40559.
28. Liu R.Y., Zhang Y., Baxter D.A., Smolen P., Cleary L.J., Byrne J.H. Deficit in long-term synaptic plasticity is rescued by a computationally predicted stimulus protocol. J. Neurosci. 2013, 33:6944-6949.
29. MacDonald E., Van der Lee H., Pocock D., Cole C., Thomas N., VandenBerg P.M., Bourtchouladze R., Kleim J.A. A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia. Neurorehabil. Neural Repair 2007, 21:486-496.
30. Mantelingu K., Kishore A.H., Balasubramanyam K., Kumar G.V., Altaf M., Swamy S.N., Selvi R., Das C., Narayana C., Rangappa K.S., Kundu T.K. Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy. J. Phys. Chem. B 2007, 111:4527-4534.
31. Marmorstein R., Trievel R.C. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim. Biophys. Acta 2009, 1789:58-68.
32. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J. Neurosci. 2001, 21:6000-6007.
33. McBride S.M.J., Choi C.H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., Sehgal A., Siwicki K.K., Dockendorff T.C., Nguyen H.T., McDonald T.V., Jongens T.A. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005, 45:753-764.
34. Park E., Kin Y., Ryu H., Kowall N.W., Lee J., Ryu H. Epigenetic mechanisms of Rubinstein-Taybi syndrome. Neuromol. Med. 2014, 16:16-24.
35. Peters M., Bletsch M., Catapano R., Zhang X., Tully T., Bourtchouladze R. RNA interference in hippocampus demonstrates opposing roles for CREB and PP1α in contextual and temporal long-term memory. Genes Brain Behav. 2009, 8:320-329.
36. Peterson J.J., Novick S.J. Nonlinear blending: a useful general concept for the assessment of combination drug synergism. J. Recept. Signal Transduct. Res. 2007, 27:125-146.
37. Petrij F., Giles R.H., Dauwerse H.G., Saris J.J., Hennekam R.C., Masuno M., Tommerup N., van Ommen G.J., Goodman R.H., Peters D.J., Breuning M.H. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995, 376:348-351.
38. Pittenger C., Huang Y.Y., Paletzki R.F., Bourtchouladze R., Scanlin H., Vronskaya S., Kandel E.R. Reversible inhibition of CREB/ATF transcription factors in region CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory. Neuron 2002, 34:447-462.
39. 2+ indicators. J. Neurosci. 2004, 24:9572-9579.
40. Popiel H.A., Takeuchi T., Fujita H., Yamamoto K., Ito C., Yamane H., Muramatsu S., Toda T., Wada K., Nagai Y. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism. PLoS One 2012, 7:e51069.
41. Rafi M.A., Rao H.Z., Luzi P., Curtis M.T., Wenger D.A. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol. Ther. 2012, 20:2031-2042.
42. Redondo R.L., Morris R.G. Making memories last: the synaptic tagging and capture hypothesis. Nat. Rev. Neurosci. 2011, 12:17-30.
43. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
44. Roelfsema J.H., Peters D.J. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev. Mol. Med. 2007, 9:1-16.
45. Rose G.M., Hopper A., De Vivo M., Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr. Pharm. Des. 2005, 11:3329-3334.
46. Rosenblum K., Futter M., Voss K., Erent M., Skehel P.A., French P., Obosi L., Jones M.W., Bliss T.V. The role of extracellular regulated kinases I/II in late-phase long-term potentiation. J. Neurosci. 2002, 22:5432-5441.
47. Scott A.I., Perini A.F., Shering P.A., Whalley L.J. In-patient major depression: is rolipram as effective as amitriptyline. Eur. J. Clin. Pharmacol. 1991, 40:127-129.
48. Severyn B., Liehr R.A., Wolicki A., Nguyen K.H., Hudak E.M., Ferrer M., Caldwell J.S., Hermes J.D., Li J., Tudor M. Parsimonious discovery of synergistic drug combinations. ACS Chem. Biol. 2011, 6:1391-1398.
49. Smolen P., Baxter D.A., Byrne J.H. A model of the roles of essential kinases in the induction and expression of late long-term potentiation. Biophys. J. 2006, 90:2760-2775.
50. Smolen P., Baxter D.A., Byrne J.H. Molecular constraints on synaptic tagging and maintenance of long-term potentiation: a predictive model. PLoS Comput. Biol. 2012, 8:e1002620.
51. 2+ and cAMP requires protein kinase A and mitogen-activated protein kinase/extracellular regulated kinase activation. J. Neurosci. 2001, 21:5484-5493.
52. Woo N.H., Duffy S.N., Abel T., Nguyen P.V. Genetic and pharmacological demonstration of differential recruitment of cAMP-dependent protein kinases by synaptic activity. J. Neurophysiol. 2000, 84:2739-2745.
53. Ying S.W., Futter M., Rosenblum K., Webber M.J., Hunt S.P., Bliss T.V., Bramham C.R. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J. Neurosci. 2002, 22:1532-1540.
54. Zentner G.E., Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Mol. Biol. 2013, 20:259-266.
55. Zhang Y., Liu R.Y., Heberton G.A., Smolen P., Baxter D.A., Cleary L.J., Byrne J.H. Computational design of enhanced learning protocols. Nat. Neurosci. 2011, 15:294-297.
56. Zhang Y., Smolen P., Baxter D.A., Byrne J.H. Computational analyses of synergism in small network motifs. PLoS Comput. Biol. 2014, 10:e1003524.
57. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.